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Abstract. Among the mechanisms that control cancer progres-
sion, cell mobility is a significant factor required for cellular 
liberation from the primary focus and infiltration. Hepatocyte 
growth factor (HGF) has been shown to facilitate cell mobility. 
In the present study, the clinical significance of the HGF/c-Met 
pathway in the assessment of gastric cancer progression was 
evaluated. From a cohort of patients with gastric cancer 
who underwent surgical resection between April 1999 
and March 2003, 110 subjects were randomly selected. 
Preoperative serum HGF levels were measured and various 
pathological factors were analyzed. Furthermore, 50 subjects 
were randomly selected from within this group and immu-
nohistochemical staining of tissue preparations for HGF and 
its receptor c‑Met were performed. In the infiltrative growth 
pattern [(INF)α,β vs. INFγ], advanced progression was associ-
ated with elevated preoperative serum HGF levels (P<0.001). 
No correlation was identified between serum HGF levels and 
immunostaining for HGF or c‑Met in the tissue preparations. 
Immunostaining revealed a significant correlation between 
c‑Met expression and lymphatic vessel invasion (ly0.1 vs. 2.3; 
P=0.0416), lymph node metastasis (n0.1 vs. 2; P=0.0184) and 
maximum tumor diameter (≤50 mm vs. >50 mm; P=0.0469). 
Furthermore, c‑Met‑positivity was associated with a significant 
difference in overall survival  (P=0.0342), despite stage I and II 
cases accounting for 82% of the total cohort (41 of 50 cases). 
These results suggested that the expression of the HGF/c-Met 
pathway in gastric cancer may be a potential predictive factor 
for disease progression.
Introduction
Among the mechanisms that mediate cancer progression, 
cell mobility is a significant factor necessary for liberation 
from the primary focus and infiltration. Various cell growth 
factors (1‑5), including epidermal growth factor, transforming 
growth factor β (6,7) and hepatocyte growth factor (HGF) (8), 
are known to facilitate cell mobility.
HGF, which was f i rst isolated and cloned by 
Nakamura et al (9‑12), performs various biological activities 
in cells, including stimulation of cell growth, promotion of 
migration, induction of morphogenesis and anti-apoptotic 
activities, via the c-Met receptor, which is a transmembrane 
protein containing a tyrosine kinase domain (13‑15). The 
involvement of HGF in the infiltration/metastasis of cancer 
cells was first suggested in 1991, in a study in which the scatter 
factor, isolated as a fibroblast‑derived bioactive factor with cell 
stimulatory activities in various cultured epithelial and cancer 
cells, was found to share an identical structure to that of the 
HGF molecule (16,17). The functions of HGF were further 
elucidated by in vitro and in vivo analyses using various types 
of cancer cell (18,19). Activation of the HGF/c-Met pathway 
leads to simultaneous activation of multiple signal transduc-
tion pathways that promote the infiltration of cancer cells 
and is considered to underlie the potent infiltrative/stimula-
tory effect of HGF (20‑25). Genetic mutations of the c‑Met 
receptor have been reported in various cancer types, including 
papillary renal (20‑21), hepatic (22), gastric (23) and pulmo-
nary cancer (24,25), and the overexpression of c‑Met has also 
been reported in numerous cancer tissues (26). Therefore, if 
the c‑Met receptor is present in cancer cells, HGF antagonists 
should be able to inhibit multiple signal transduction pathways 
that lead to cancer cell infiltration, thereby exerting potential 
anti-cancer effects (27).
In a previous study by our group, an association between 
elevated pre-operative serum HGF levels and advanced 
disease stages in colon cancer was identified, mainly regarding 
the depth of tumor invasion into the wall and liver metastasis, 
which suggested the expression of the HGF/c-Met pathway as 
a potential predictive factor of colon cancer progression (8). In 
the present study, serological and immunohistological analyses 
were conducted in order to evaluate the clinical significance 
of the expression of the HGF/c-Met pathway in assessing the 
stage of gastric cancer progression.
Materials and methods
Patients. Subjects (n=110) were randomly selected from a 
cohort of patients with gastric cancer who underwent surgical 
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resection at the Department of Surgery II, Tokyo Women's 
Medical University (Tokyo, Japan) between April 1999 and 
March 2003. Verbal consent was obtained from all patients 
upon hospitalization and written consent was obtained on the 
inpatient treatment plan. The study was conducted in 2005 
in accordance with the ethical guidelines established by the 
updated Declaration of Helsinki and Tokyo Women's Medical 
University. Preoperative serum HGF levels in these subjects 
were measured and various pathological factors were analyzed. 
For 50 of these patients, immunohistochemical staining of 
tissue preparations for HGF and c‑Met was additionally 
performed in order to analyze various factors identified in 
serological analysis.
The subjects comprised 83 males and 27 females aged 
29‑84 years [mean ± standard deviation (SD), 62.8±9.9 years]. 
The tissue samples were histologically classified as follows: 
Four as papillary adenocarcinoma, 51 as tubular adeno-
carcinoma (25 as well‑differentiated and 26 as moderately 
differentiated), 45 as poorly differentiated adenocarcinoma, six 
as signet‑ring cell carcinoma and three as mucinous adenocar-
cinoma. The histological classification of invasion depth was 
as follows: Mucosa (m) in 28 patients, submucosa (sm) in 31 
patients, muscularis propria (mp) in 11 patients, subserosa (ss) 
in 18 patients and serosa (se) in 22 patients. The stage classifi-
cation was IA in 55 patients, IB in 18 patients, II in 16 patients, 
IIIA in nine patients, IIIB in six patients and IV in six patients 
(Table I). Data obtained from 200 healthy individuals were 
used as the control. Healthy individuals comprised patients 
undergoing surgery for benign diseases, including inguinal 
hernia or hemorrhoid, and healthy volunteers. Classification 
of infiltrative growth pattern (INF) was performed according 
to the General Rules for the Gastric Cancer Society, by the 
Japanese Research Society for Gastric Cancer, which is based 
on the Union for International Cancer Control criteria (28).
The 50 subjects that were subjected to immunostaining 
comprised 38 males and 12 females, with a mean age of 
61.8±10.6 years (range, 29‑81 years). The tissue samples were 
histologically classified as follows: One as papillary adenocar-
cinoma, 23 as tubular adenocarcinoma (12 well‑differentiated 
and 11 moderately differentiated), 20 as poorly differentiated 
adenocarcinoma, five as signet‑ring cell carcinoma and one 
as mucinous adenocarcinoma. The histological classification 
of invasion depth was as follows: m in 13 patients, sm in 
15 patients, mp in five patients, ss in eight patients and se in 
nine patients. The stage classification was IA in 25 patients, IB 
in seven patients, II in nine patients, IIIA in four patients, IIIB 
in two patients and IV in three patients (Table II).
Serological analysis. Serum was obtained by centrifugation of 
venous blood collected prior to surgery at 1,000‑2,000 x g for 
10 min, which was stored frozen at -80˚C and thawed at the time 
of measurement. HGF levels were measured using a two‑step 
sandwich HGF ELISA kit (Otsuka, Tokyo, Japan), which 
included the antibodies and o‑Phenylenediamine substrate solu-
tion, according to the manufacturer's instructions. In the first 
reaction, 50 µl phosphate‑buffered saline (PBS; Wako Pure 
Chemical Industries, Ltd, Osaka, Japan) and 50 µl sample were 
added to each well of a microtiter plate, which was sealed and 
incubated at room temperature for 1 h with agitation. Following 
removal of the reaction mixture, the plate was washed five 
times with wash buffer (Wako Pure Chemical Industries, Ltd). 
Subsequently, 100 µl/well rabbit polyclonal anti‑HGF primary 
antibody was added for the second reaction and incubated for 
1 h at room temperature. Following aspiration and washing five 
times, 100 µl/well of the horseradish peroxidase‑conjugated 
goat anti‑rabbit immunoglobulin G secondary antibody was 
added for the third reaction and incubated for 1 h at room 
temperature. Following aspiration and washing five times, 
100 µl/well o‑Phenylenediamine substrate solution was added. 
Following incubation at room temperature for 10 min, the reac-
tion was stopped by adding 100 µl of stop solution. Absorbance 
was measured at 420 nm using a microplate reader (SpectraMax 
Plus 384; Molecular Devices, Sunnyvale, CA, USA), and HGF 
levels were determined using a standard curve.
Immunohistological analysis. HGF: Following deparaffiniza-
tion with petroleum benzene (Kanto Chemical Co., Inc., 
Tokyo, Japan) of the 20% formalin‑fixed (Wako Pure Chemical 
Industries, Ltd) paraffin‑embedded (Junsei Chemical Co., Ltd, 
Tokyo, Japan) sections (4 µm), which included the innermost 
tumor portion of each gastric cancer primary focus, the sections 
were immersed in PBS and exposed to microwaves at 95˚C 
for 15 min to activate the antigens. Subsequently, the tissue 
sections were treated with 3% H2O2 (Sankyo Kagaku Yakuhin 
Co., Ltd, Kanagawa, Japan) for 20 min to remove the intrinsic 
peroxidase activity and immunohistochemical staining was 
performed using the avidin‑biotin‑peroxidase complex (ABC) 
method. Following dilution of the reaction with normal horse 
serum at room temperature for 10 min, rabbit polyclonal 
anti‑human HGF antibody (dilution, 1:20; IBL Co., Ltd, 
Gunma, Japan) was used as the primary antibody and incu-
bation was continued at room temperature for 60 min. This 
was followed by reaction with a biotin‑conjugated anti‑mouse 
immunoglobulin G secondary antibody (DAKO Japan, 
Kyoto, Japan) at room temperature for 30 min and reaction 
with the ABC reagent (DAKO, Glostrup, Denmark) at room 
temperature for 30 min. The color was developed by addition 
of 20% 3,3'‑diaminobenzidine tetrahydrochloride (Dojindo 
Laboratories, Kumamoto, Japan), the nuclei were stained with 
hematoxylin (Merck Millipore KGaA, Darmstadt, Germany) 
and the sections were dehydrated.
c‑Met: c‑Met was assayed in a similar manner to HGF, 
except that the antigen was activated by autoclaving at 95˚C 
for 15 min and a rabbit polyclonal anti‑human c‑Met primary 
antibody (dilution, 1:20; IBL Co., Ltd.) was allowed to react at 
room temperature for 1 h.
Microscopic examination of HGF and c‑Met was 
performed on the tip of the tumor, particularly the inner-
most section. Three fields of each section were observed at 
200x magnification using a BHS/System Living microscope 
(Olympus Corp., Tokyo, Japan) and the results were clas-
sified as positive when the ratio of stained cancer cells was 
>25%, according to previous studies that were analyzed for 
comparison (Fig. 1) (8,29‑31).
Statistical analysis. JMP version 9.0.2 statistical software (SAS 
Institute, Inc., Cary, NC, USA) was used for statistical analyses. 
Values are presented as the mean ± SD. The Mann‑Whitney 
U test was used to compare differences between two independent 
groups. Cumulative survival rates were calculated using the 
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Table I. Clinicopathological factors and serum HGF.
 
Factor n Serum HGF (pg/ml) P‑value
 
Gastric cancer 110 391.02±68.44 <0.0001
Control 200 193.30±52.00 
Stagea 
  ⅠA 55 381.21±65.92 NS
  ⅠB 18 414.41±82.48 
  Ⅱ 16 378.28±47.01 
  ⅢA 9 404.64±65.95 
  ⅢB 6 402.38±93.44 
  Ⅳ 6 412.94±71.45 
Depth 
  m 28 378.89±58.81 NS
  sm 31 384.87±69.89 
  mp 11 386.97±98.72 
  ss 18 403.36±54.88 
  s 22 407.04±71.75 
INFa 
  α 22 369.65±68.93 <0.001 (α.β vs. γ)
  β 37 367.34±59.68 
  γ 44 418.42±67.72 
Histological type 
  well 25 387.23±54.56 NS
  mod 26 379.56±80.35 
  poor 45 399.25±70.48 
  sig 6 404.95±74.10 
  muc 3 361.36±77.65 
  pap 4 396.12±54.23 
Macroscopic type 
  0 59 382.03±64.39 NS
  0‑advanced 9 364.13±68.61 
  1 4 426.32±66.53 
  2 16 404.70±87.33 
  3 10 402.00±43.63 
  4 11 423.53±72.43 
  5 1 335.54±0.000 
Lymphatic invasion 
  ly0 48 384.71±63.69 NS
  ly1 37 391.22±70.67 
  ly2 21 398.01±76.63 
  ly3 4 428.13±68.74 
Venous invasion 
  v0 89 387.92±67.32 NS
  v1 20 404.99±75.03 
  v2 1 387.52±0.000 
Lymph node metastasis 
  n0 78 391.17±70.37 NS
  n1 17 382.79±58.94 
  n2 13 394.60±68.08 
  n3 0  
  n4 2   431.73±116.00 NS
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Kaplan‑Meier method and distributions were identified using 
the log‑rank test. P<0.05 was considered to indicate a statisti-
cally significant difference between values.
The terminology used in this report is in accordance 
with the General Rules of the Gastric Cancer Society by the 
Japanese Research Society for Gastric Cancer (28).
Results
Serological analysis of HGF. Significant differences were 
detected in preoperative HGF levels between the gastric cancer 
and control groups (391.0±68.4 vs. 193.3±52.0 pg/ml, respec-
tively; P<0.0001). There was no correlation between preoperative 
serum HGF levels and patient age or gender. The results of 
analyses to identify correlations between serum HGF levels 
and clinicopathological factors are shown in Table I. Advanced 
progression in the INFα/β vs. INFγ was correlated with elevated 
preoperative serum HGF levels (P<0.001). Although there was 
no significant difference in tumor diameter, invasion depth or 
lymphatic vessel invasion (ly), preoperative serum HGF levels 
increased as the disease progressed. In patients with peritoneal 
dissemination, serum HGF levels were frequently increased.
Figure 1. Immunostaining of HGF and c‑Met. Microscopic examination was conducted on the tip of the tumor, particularly the innermost part. By observing 
three fields at 200x magnification, the results were classified as positive if the ratio of stained cancer cells was >25%, as analyzed by comparison. (A) Negative 
HGF staining. (B) Positive HGF staining. (C) Negative c‑Met staining. (D) Positive c‑Met staining. HGF, hepatocyte growth factor.
Table I. Continued.
 
Factor n Serum HGF (pg/ml) P‑value
 
Peritoneal dissemination 
  p0 105 389.37±68.19 NS
  p1 5 425.58±71.99 
Tumor size, mm 
  ≤–70 97 384.64±66.22 NS
  >70 10 428.09±61.82 
 
aClassification of INF was performed according to the General Rules for the Gastric Cancer Society by the Japanese Research Society for 
Gastric Cancer. Values are expressed as the mean ± standard deviation. HGF, hepatocyte growth factor; NS, not significant; m, mucosa; sm, 
submucosa; mp, muscularis propria; ss, subserosa; s, serosa; INF, infiltrative growth pattern; INFα, expansive type (tumor margin is clear); 
INFβ, intermediate type; INFγ, invasive type (tumor margin is unclear); well, well-differentiated tubular adenocarcinoma; mod, moderately 
differentiated tubular adenocarcinoma; poor, poorly differentiated adenocarcinoma; sig, signet‑ring cell carcinoma; muc, mucinous adenocar-
cinoma; pap, papillary adenocarcinoma.
 
  A   B
  C   D
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Table II. Correlation between HGF/c‑Met overexpression and clinicopathological factors.
  HGF expression c‑Met expression
 ---------------------------------------------------------- -------------------------------------------------------
Factor n subtotal (-) (+) P‑value (-) (+) P‑value
All 50  14 36  25 25 
Gender 
  Male 38
  Female 12
Stage 
  ⅠA 25 41 12 29 NS 23 18 NS
  ⅠB 7
  Ⅱ 9
  ⅢA 4 9 2 7  2 7
  ⅢB 2
  Ⅳ 3
Depth 
  m 13 13 5 8 NS 9 4 NS
  sm 15 37 9 28  16 21
  mp 5
  ss 8
  se 9
INF 
  α 10 32 10 22 NS 16 16 NS
  β 22 
  γ 17 17 3 14  8 9 
Histological type 
  well 12 23 5 18 NS 11 12 NS
  mod 11 
  poor 20 25 8 17  13 12 
  sig 5 
  muc 1 
  pap 1 
Lymphatic invasion 
  ly0 27 43 12 31 NS 24 19 0.0416
  ly1 16 
  ly2 4 7 2 5  1 6 
  ly3 3 
Venous invasion 
  v0 43 43 11 32 NS 23 20 NS
  v1 7 7 3 4  2 5 
  v2 0 
Lymph node metastasis 
  n0 34 45 12 33 NS 25 20 0.0184
  n1 11
  n2 5 5 2 3  0 5 
  n3 0 
  n4 0 
Peritoneal dissemination 
  p0 47 47 14 33 NS 24 23 NS
  p1 3 3 0 3 NS 1 2 NS
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Immunohistological analysis. Of the 50 cases analyzed, 36 
(72%) were HGF‑positive and 14 (28%) were HGF‑negative, 
whereas 25 (50%) were c‑Met‑positive and 25 (50%) were 
c‑Met‑negative. No correlation was found between serum HGF 
levels in either staining. There was no correlation between 
the pathological factors analyzed and HGF levels, whereas a 
significant correlation was found between c‑Met, which is a 
receptor of HGF, and lymphatic vessel invasion (ly0.1 vs. 2.3; 
P=0.0416), lymph node metastasis (n0.1 vs. 2; P=0.0184) and 
maximum tumor diameter (≤50 mm vs. >50 mm; P=0.0469) 
(Table II). The overall survival (OS) was significantly 
lower in c-Met-positive cases than that in c-Met-negative 
cases  (P=0.0342; Fig. 2 and Table III).
Discussion
Cell growth factors, including HGF, constitute a significant 
group of molecules that regulate cell proliferation, migration 
and apoptosis in the dynamic organization of cell populations 
during embryogenesis, organogenesis and regeneration. 
Numerous factors amongst these additionally promote cell 
migration. It has been previously reported that HGF has the 
most potent effect on the promotion of cancer cell infiltra-
tion, the cell migration associated with the degradation of 
extracellular matrix components, including the basement 
membrane and collagen (9‑16). Therefore, activation of the 
HGF/c‑Met pathway results in the simultaneous activation of 
multiple signal transduction pathways that promote cancer cell 
infiltration. Antagonists of the HGF/c-Met pathway represent 
potential anti-cancer agents to inhibit cancer infiltration and 
metastasis, and therefore, the development of such antagonists 
is currently underway (27).
In the present study, serological and immunohistological 
analyses of the expression of the HGF/c-Met pathway in 
gastric cancer were performed in order to establish its clin-
ical significance in the assessment of disease progression. 
To the best of our knowledge, no previous studies analyzing 
serum HGF levels and immunostaining for HGF and c‑Met 
simultaneously with pathological factors were available in 
the literature.
Although elevated serum HGF levels in patients with 
gastric cancer had been previously reported (32‑35), the 
present study aimed to determine whether this factor may be 
used in the assessment of disease progression. The results indi-
cated that pre-operative serum HGF levels were significantly 
higher in patients with gastric cancer than those in the control 
group (P<0.0001), and that high HGF levels above the cut‑off 
value (297.3 pg/ml; mean in the control+2 SD) were observed 
in 93.75% of patients, similar to that reported previously. 
However, the correlation between HGF levels and disease stage 
previously reported by Wu et al (32) and Han et al (33) was not 
observed in the present study, the results of which were similar 
to those reported by Taniguchi et al (34).
Conversely, advanced progression in the infiltrating 
growth pattern (INFα/β vs. INFγ) was significantly correlated 
with high preoperative serum HGF levels (P<0.001). Although 
this effect may be associated with the involvement of HGF in 
the infiltrating growth of cancer cells, this factor could not be 
Table II. Continued.
  HGF expression c‑Met expression
 -------------------------------------------------------- ------------------------------------------------------
Factor n subtotal (-) (+) P‑value (-) (+) P‑value
Tumor size (mm) 
  ≤50 38 38 12 26 NS 22 16 0.0469
  >50 12 12 2 10  3 9 
Serum HGF (pg/ml) 
  ≤400 36 36 10 26 NS 17 19 NS
  >400 14 14 4 10  8 6 
Mean age (standard deviation) of subjects, 61.8 (10.6) years. HGF, hepatocyte growth factor; SD, standard deviation; NS, not significant; m, 
mucosa; sm, submucosa; mp, muscularis propria; ss, subserosa; s, serosa; INF, infiltrative growth pattern; INFα, expansive type (tumor margin 
is clear); INFβ, intermediate type; INFγ, invasive type (tumor margin is unclear); well, well-differentiated tubular adenocarcinoma; mod, 
moderately differentiated tubular adenocarcinoma; poor, poorly differentiated adenocarcinoma; sig, signet‑ring cell carcinoma; muc, mucinous 
adenocarcinoma; pap, papillary adenocarcinoma.
Figure 2. c‑Met immunostaining and OS of subjects. OS of c‑Met 
immunopositive cases (n=25) was significantly lower than that of c‑Met 
immunonegative cases (n=25); log‑rank test, P=0.0342. (A) Negative c‑Met 
immunostaining. (B) Positive c‑Met immunostaining. OS, overall survival.
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evaluated because, to the best of our knowledge, no other study 
on infiltrating growth patterns was available in the literature.
HGF levels were not significantly correlated with certain 
parameters, including tumor diameter, invasion depth and ly 
factors; however, preoperative serum HGF levels were elevated 
as the disease progressed. Regarding the association between 
HGF levels and invasion depth (pT factor), Niki et al (35) iden-
tified a significant difference between pT1 and pT2‑4 tumors.
Although a significant difference in HGF levels was not 
detected in patients with peritoneal dissemination, there was a 
tendency towards high HGF levels among these patients.
Subjects for the present study were selected randomly; there-
fore no patient with liver metastasis was included. Niki et al (35) 
reported a significant elevation in serum HGF levels in patients 
diagnosed with liver metastasis, whereas Taniguchi et al (34) 
reported that there was no significant difference in serum HGF 
Table III. Five-year survival rate and P‑value for overall survival.
Clinicopathological factor n Five-year survival rate  P‑value 
Peritoneal dissemination  
  p0 47 0.893 <0.0001 (p0 vs. 1)
  p1 3 0.000 
Stage
  Ⅰ/Ⅱ 41 0.975 <0.0001 (Ⅰ/Ⅱ vs. Ⅲ/Ⅳ)
  Ⅲ/Ⅳ 9 0.222 
Tumor size (mm) 
  <50 38 0.920 0.0001 (<50 vs. >50)
  >50 12 0.583 
Venous invasion  
  v0 43 0.906 0.0011 (v0 vs. 1/2)
  v1/2 7 0.429 
Lymphatic invasion   
  ly0/1 43 0.906 0.0017 (ly0/1 vs. 2/3)
  ly2/3 7 0.429 
Lymph node metastasis  
  n0/1 45 0.888 0.0056 (n0/1 vs. 2)
  n2 5 0.400 
Infiltrative growth pattern  
  IFNα/β 32 0.937 0.0083 (IFNα/β vs. γ)
  IFNγ 17 0.647 
c-Met expression 
  (-) 25 0.920 0.0342 [(-) vs. (+)]
  (+) 25 0.758 
serum HGF (pg/ml) 
  <400 36 0.887 0.0558 (<400 vs. >400)
  >400 14 0.714 
Histological type  
  well/mod 23 0.920 0.1793 (well/mod vs. por/sig)
  poor/sig 25 0.756 
Depth  
  m 13 0.917 0.2649 (m vs. sm/mp/ss/se)
  sm/mp/ss/se 37 0.811 
HGF expression 
  (-) 14 0.929 0.5385 [(-) vs. (+)]
  (+) 36 0.806 
HGF, hepatocyte growth factor; m, mucosa; sm, submucosa; mp, muscularis propria; ss, subserosa; s, serosa; INF, infiltrative growth pattern; 
INFα, expansive type (tumor margin is clear); INFβ, intermediate type; INFγ, invasive type (tumor margin is unclear); well, well-differentiated 
tubular adenocarcinoma; mod, moderately differentiated tubular adenocarcinoma; poor, poorly differentiated adenocarcinoma; sig, signet‑ring 
cell carcinoma; muc, mucinous adenocarcinoma; pap, papillary adenocarcinoma. 
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levels in patients with relapse independent of liver metastasis. 
Therefore, the preoperative serum HGF levels in patients with 
gastric cancer represent a potential predictive factor for disease 
progression, as observed in colon cancer (6).
In the present study, no correlation was identified between 
serum HGF levels and immunostaining for HGF or c‑Met in 
tissue preparations; this was potentially due to the complex 
paracrine and autocrine mechanisms of HGF in cancer 
cells (36,37). Therefore, the significance of HGF expression 
in the microenvironment surrounding tumors requires further 
investigation.
Although there was no correlation between pathological 
factors and immunostaining for HGF, a significant correlation 
was identified between c‑Met, which is a receptor of HGF, and 
lymphatic vessel invasion (ly0.1 vs. 2.3, P=0.0416), lymph 
node metastasis (n0.1 vs. 2, P=0.0184) and maximum tumor 
diameter (<50 mm vs. >50 mm, P=0.0469). Correlations 
between immunostaining for c‑Met and various pathological 
factors, particularly invasion depth and disease stage, have 
been reported in previous studies (38‑46). In the present 
study, cases were selected randomly for immunostaining 
analysis, as for serological analysis. It was demonstrated that 
41 (82%) of the 50 cases analyzed were stage I or II, and 
28 (56%) had an invasion depth of m or sm, indicating that 
the majority of the cohort comprised relatively early stage 
cancer cases. Only three (6%) cases that were Peritoneum 
dissemination-factor-positive were stage IV. These results 
likely explain the absence of statistically significant differ-
ences between immunostaining and invasion depth or disease 
stage.
However, in the present study, which included numerous 
relatively early cancer cases, the OS of c‑Met immunos-
taining‑positive cases was significantly lower than that of 
negative cases (P=0.0342), indicating that c‑Met positivity 
may be a prognostic factor for gastric cancer.
In chemotherapy for unresectable recurrent gastric 
cancer, the efficacy of trastuzumab was demonstrated in 
HER2‑positive cases, which subsequently led to the use 
of personalized drug treatments with molecularly targeted 
drugs (47). Rilotumumab, which is a fully human monoclonal 
antibody against HGF and a ligand of the c‑Met receptor, 
suppresses c‑Met downstream signaling (47). In pre-clinical 
models, rilotumumab was shown to inhibit tumor progression 
in a HGF/c‑Met‑ dependent manner, and its tolerability was 
verified in early clinical trials (48,49). If future phase II/III 
trials are implemented under clinical trial designs that allow 
sufficient verification of the potential of c‑Met expression as 
a biomarker to aid the identification of cases in which rilo-
tumumab is effective, a field of c‑Met‑positive gastric cancer 
may be established, similarly to that of HER2‑positive gastric 
cancer. Therefore, further basic studies regarding c‑Met 
expression are required, particularly to improve quality 
control in immunostaining.
In conclusion, the results of the present study revealed 
that elevated pre-operative serum HGF levels were indicative 
of invasive growth of tumor foci, categorized as IFNγ, and 
characterized by high-grade tumors with an unclear border 
between the tumor and the surrounding tissue. c‑Met-positive 
immunostaining indicated a tumor with a large diameter, 
advanced lymphatic vessel invasion and a high degree of 
lymph node metastasis, and may therefore be a factor indi-
cating poor prognosis. Based on the results described above, 
the expression of the HGF/c-Met pathway in gastric cancer is 
a potential predictive factor for disease progression, as previ-
ously established for colon cancer.
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